United States Digital Biomarkers Market Forecast to Reach US$ 39.28 Billion by 2033, Neurological Disease Monitoring and AI Analytics Accelerate Market Growth

The Digital Biomarkers Market size was US$ 6.18 Billion in 2025 and is expected to reach US$ 39.28 Billion by 2033, growing at a CAGR of 22.7% during the forecast period 2026-2033.

The market is experiencing significant growth as healthcare providers, pharmaceutical companies, and research organizations increasingly adopt digital biomarkers to enable continuous, objective, and real-time patient monitoring. Rising adoption of wearable devices, mobile health applications, and artificial intelligence-driven analytics is further supporting the integration of digital biomarkers across clinical research, disease management, and personalized healthcare.

Industry participants are focusing on expanding validated digital health platforms, strengthening AI-powered data analytics capabilities, and forming strategic collaborations with healthcare institutions and life sciences companies to improve clinical decision-making and patient outcomes. As regulatory acceptance and digital health infrastructure continue to evolve, early adopters are well positioned to capitalize on expanding opportunities in remote monitoring, decentralized clinical trials, and precision medicine.

Get a Free Sample PDF of this Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/digital-biomarkers-market?ram

Key Industry Developments

United States:
✅ June 2026: Autism Diagnostics Lab launched the MDMTM Gut & Brain Health Test, the first commercial urine-based metabolomics-based autism screening test designed to identify digital biological signatures associated with autism risk. Built on Arizona State University research, the non-invasive platform supports earlier clinical decision-making through measurable biomarker analysis. It represents a significant advancement in digital biomarker-enabled precision diagnostics for neurodevelopmental disorders.

✅ January 2026: Tempus AI introduced Paige Predict, an AI-powered digital pathology solution that predicts clinically actionable biomarkers directly from H&E tissue images. The platform enables physicians to identify potential molecular biomarkers before comprehensive genomic testing, accelerating precision oncology workflows. The launch strengthens the integration of AI-derived digital biomarkers into routine cancer diagnostics.

✅ October 2025: Roche Diagnostics received U.S. FDA clearance for its Elecsys® pTau181 blood test, enabling primary care physicians to assess Alzheimer's-related amyloid pathology using a validated blood biomarker. The innovation broadens access to earlier cognitive disease evaluation while reducing reliance on invasive diagnostic procedures. The approval marked a major milestone in biomarker-driven neurological diagnostics.

Japan:
✅ June 2026: SOXAI announced that its proprietary SOXAI OSTM vital sensing platform would power Sharp's first smart ring, expanding continuous physiological monitoring through advanced sensor algorithms and biometric analytics. The collaboration enhances real-time collection of wearable-derived digital biomarkers for everyday health monitoring. The partnership demonstrates Japan's continued innovation in wearable digital biomarker technologies.

✅ April 2026: Sysmex Corporation launched the HISCLTM p-Tau217 Assay Kit for Research Use, enabling quantitative measurement of the Alzheimer's biomarker p-Tau217 from blood samples. Following its European debut, the company announced sequential expansion into Japan and other global markets to accelerate Alzheimer's biomarker research. The assay supports less invasive biomarker-based neurological research and future diagnostic development.

✅ December 2025: AMI Inc. obtained Japanese regulatory approval for its Digital Biomarker DNP-AS software for use with electronic stethoscopes. The AI-powered medical device analyzes heart sound data to generate clinically meaningful digital biomarkers, supporting earlier cardiovascular assessment and remote healthcare applications. The approval represents a notable advancement in Japan's digital biomarker and AI-enabled medical device ecosystem.

Strategic Acquisitions & Partnerships
✅ Roche - Acquisition (PathAI)
(May, 2026)
Roche entered into a definitive merger agreement to acquire PathAI, an AI-powered digital pathology company, for an upfront payment of US$750 million plus milestone payments. The acquisition strengthens Roche's digital pathology and precision diagnostics portfolio by combining PathAI's AI platform with Roche's companion diagnostics capabilities to accelerate biomarker discovery and AI-enabled diagnostic development.

✅ Huma & Samsung Electronics
- Strategic Partnership
(June, 2026)
Huma (through its CRO subsidiary Alcedis) partnered with Samsung Electronics to advance wearable-derived digital biomarker development and digital clinical endpoints. The collaboration enables protocol-specific biosensor data capture, raw signal access, and integrated clinical trial execution to accelerate regulatory-grade digital biomarker validation.

Key Players:
Koneksa Health | Altoida Inc. | Empatica Inc. | Evidation Health, Inc. | ActiGraph LLC | Quartet Health | IXICO plc | VivoSense | Aural Analytics | Neurotrack Technologies, Inc.

Key Highlights: Top 5 Key Players in Digital Biomarkers Market 2026
-Koneksa Health: Launched LodestarTM Intelligent Submission Software in 2026, an AI-assisted, audit-ready regulatory submission platform that unifies clinical data, digital biomarker workflows, and FDA/EMA submission processes while significantly reducing biometrics programming time and accelerating digital endpoint adoption in clinical trials.

-Empatica Inc.: Expanded its Parkinson's Monitoring Platform with CE MDR-certified PKG Measures and advanced the EmbraceMini wearable ecosystem, enabling continuous remote monitoring, richer digital endpoints, and clinically validated digital biomarker collection for decentralized clinical trials.

-Evidation Health, Inc.: Introduced the Temporal Proteomics Platform in 2026, integrating longitudinal digital health data with proteomics to strengthen biomarker discovery, autoimmune disease research, and real-world evidence generation for precision medicine.

-Altoida Inc.: Advanced its AI/AR-powered Digital NeuroMarker Platform through a 2026 collaboration with Mindspan, expanding objective digital cognitive biomarker assessment for Alzheimer's disease by enabling rapid, self-administered cognitive screening and earlier clinical decision-making.

-Aural Analytics: Continued expanding its speech-based digital biomarker platform through clinical development collaborations supporting AI-powered vocal biomarker analysis for neurological disorders, enhancing objective speech endpoint measurement in Parkinson's disease and other neurodegenerative clinical trials.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/digital-biomarkers-market?ram

Regional Insights:
-North America: 48.1% (Largest share, 2025; driven by widespread adoption of wearable technologies, strong pharmaceutical R&D, decentralized clinical trials, and favorable regulatory support.)

-Asia Pacific: (Fastest-growing region, supported by expanding digital health infrastructure, increasing healthcare expenditure, rising chronic disease burden, and government initiatives across China, Japan, South Korea, and India.)

-Europe: (Second-largest regional market, benefiting from strong digital health adoption, clinical research activity, and regulatory acceptance of digital endpoints.)

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=digital-biomarkers-market?ram

Market Segmentation Analysis:
-By System Component: Wearable Devices Lead Through Continuous Physiological Monitoring
Wearable devices represent the leading system component, driven by their ability to continuously capture physiological and behavioral data such as heart rate, activity, sleep patterns, and ECG signals for real-time health monitoring. Mobile applications complement wearables by collecting patient-reported outcomes and enabling remote engagement through smartphones. Sensors, including biosensors and motion sensors, provide high-quality data for clinical-grade monitoring across multiple therapeutic areas. Digital platforms, data integration, and analytics platforms transform raw health data into actionable clinical insights using AI and advanced analytics, while other components, such as cloud infrastructure and connectivity solutions, support secure data storage, interoperability, and scalable deployment.

-By Application: Neurological Disorders Remain the Primary Application Area
Neurological disorders represent the largest application segment, as digital biomarkers enable continuous assessment of diseases such as Parkinson's disease, Alzheimer's disease, epilepsy, and multiple sclerosis through objective monitoring of movement, cognition, and speech. Cardiovascular diseases also account for a significant application, leveraging wearable ECG and heart rhythm monitoring for early detection and disease management. Respiratory disorders utilize digital biomarkers to monitor breathing patterns and disease progression remotely, while metabolic disorders benefit from continuous glucose and lifestyle monitoring. Gastrointestinal disorders and other emerging applications are expanding as digital health technologies improve disease tracking and personalized care.

-By End User: Pharmaceutical Companies Drive Market Adoption
Pharmaceutical companies are the leading end users, utilizing digital biomarkers to enhance clinical trials, accelerate drug development, improve patient stratification, and generate real-world evidence. Healthcare providers increasingly adopt digital biomarker solutions for remote patient monitoring, early diagnosis, and personalized treatment planning across chronic diseases. Payers leverage digital health data to support value-based care models, optimize reimbursement decisions, and improve healthcare outcomes. Academic and research institutions play a vital role in validating novel digital biomarkers, advancing clinical research, and developing AI-driven diagnostic models, while other stakeholders continue expanding adoption across the digital health ecosystem.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.